NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - General · USD

Amgen Inc. (AMGN) Stock Analysis

Amgen Inc. (AMGN) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AMGN

$438.34

−$0.60 (−0.14%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AMGN with… →

AMGN Key Statistics

As of Oct 21, 2026
Trading
Open
$441.00
Previous Close
$438.94
Day's Range
434.53–441.00
52-Week Range
288.00–447.03
Volume
2.26M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.41
Valuation
Market Cap
$236.98B
P/E Ratio
27.23
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
17.91
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
2.62
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.22
EPS (ttm)Profit attributable to each share over the last twelve months.
16.10
Financials (FY)
Revenue (FY)
$36.75B+9.95%
Net Income (FY)
$7.71B+88.53%
Profit marginThe share of revenue left as profit after all costs and taxes.
22.95%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
540.63M
1-Year Return
+49.60%
Dividend and dates
Dividend
$10.08+2.30%
Ex-Dividend Date
August 21, 2026
Earnings Date
November 3, 2026
Avg Volume
2.81M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AMGN closed at $438.34, +49.60% over 1 year.

Amgen Inc. (AMGN) has a market capitalization of $236.98B.

In fiscal 2025, AMGN reported revenue of $36.75B.

AMGN Stock Return by Calendar Year

Amgen Inc. (AMGN) 10-year return: what $10,000 became

1 year
$10,000 $14,960
+49.60%
5 years
$10,000 $24,505
+145.05%
10 years
$10,000 $37,262
+272.62%

If you had invested $10,000 in Amgen Inc. (AMGN) 10 years ago, at the close on October 21, 2016, it would have been worth $37,262 at the close on October 21, 2026: +272.62% in total, +14.06% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+36.66%
2025+29.67%
2024−6.77%
2023+13.46%
2022+20.43%
2021+0.87%
2020−1.99%
2019+27.60%
2018+15.23%
2017+22.27%
2016 (partial year)−14.59%

As of October 21, 2026.

AMGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$36.75B$7.71B21.0%
2024$33.42B$4.09B12.2%
2023$28.19B$6.72B23.8%
2022$26.32B$6.55B24.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$36.75B$24.71B$9.08B$7.71B21.0%
2024$33.42B$20.57B$7.26B$4.09B12.2%
2023$28.19B$19.74B$7.90B$6.72B23.8%
2022$26.32B$19.92B$9.57B$6.55B24.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AMGN Dividend History

$9.52+5.8% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$7.563—
2025$9.524+5.8%
2024$9.004+5.6%
2023$8.524+9.8%
YearDividends per sharePaymentsChange
2026 (partial year)$7.563—
2025$9.524+5.8%
2024$9.004+5.6%
2023$8.524+9.8%
2022$7.764+10.2%
2021$7.044+10.0%
2020$6.404+10.3%
2019$5.804+9.8%
2018$5.284+14.8%
2017$4.604+360.0%
2016$1.001—

Most recent payment: $2.52 per share, ex-dividend August 21, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

AMGN Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricAMGNDrug Manufacturers - General medianvs median
P/E27.2325.238% above
P/S ratio6.223.2393% above
Profit margin22.95%9.80%13.2 pts above

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Amgen Inc. (AMGN) is capitalised at $236.98B on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry. Headcount on file is 31,500.

The 52-week range on file runs from $288.00 to $447.03. The most recent close on file for AMGN is $438.34, dated October 21, 2026. That is −$0.60 (−0.14%) against the previous close. The latest close sits 52.2% above that 52-week low.

Financial Health

In fiscal 2025, Amgen Inc. reported revenue of $36.75B. That is +9.95% against the prior fiscal year, when revenue was $33.42B. Net income for the same year was $7.71B. That is +88.53% against the prior fiscal year. The reported profit margin is 22.95%. That is 13.2 percentage points above the Drug Manufacturers - General median of 9.8%. Earnings per share on a trailing basis come to 16.1.

Across the 4 fiscal years on file, revenue moves from $26.32B in 2022 to $36.75B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 27.23. That is 7.93% above the Drug Manufacturers - General median of 25.23. On forward earnings the ratio is 17.91. The PEG ratio, which sets the P/E against expected earnings growth, reads 2.62. The price-to-sales ratio is 6.22. On price-to-sales that is 92.64% above the Drug Manufacturers - General median of 3.23. 21 Drug Manufacturers - General companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.41. Annualized volatility over the trailing 10 years is 25.34%. Over the trailing twelve months the total return is +49.60%. Across 10 years the annualized return works out at +14.06%.

Growth & Income

AMGN pays a dividend yielding 2.3%. The indicated annual rate is $10.08 a share. The ex-dividend date on file is August 21, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $7.56 a share. The year before, 2025, totalled $9.52 a share.

The strongest complete calendar year on file is 2025 at +29.67%; the weakest is 2024 at −6.77%. Of the 9 complete calendar years on file, 7 finished higher. So far in 2026 the total return is +36.66%.

Peer Comparison

Amgen Inc. (AMGN) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Amgen Inc. AMGN $236.98B 27.2
Eli Lilly and Company LLY $1.13T 42.7
Johnson & Johnson JNJ $621.22B 39.1
AbbVie Inc. ABBV $503.27B 80.5

The Drug Manufacturers - General industry average P/E ratio is 25.2x. Amgen Inc. trades at a P/E of 27.2.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 MRK

Merck & Co., Inc.

$369.78B

 NVS

Novartis AG

$292.58B

 AZN

AstraZeneca PLC

$261.82B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$374.30B

 TMO

Thermo Fisher Scientific Inc.

$256.61B

 GILD

Gilead Sciences, Inc.

$190.42B

 ABT

Abbott Laboratories

$173.92B

 NVO

Novo Nordisk A/S

$172.38B
View all Healthcare stocks →

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Visit website →